Our study found that LCZ696 treatment was associated with a reduction in HF rehospitalization without significant effects on mortality, NT‐proBNP, and Rv5 + Sv1. LCZ696 is safe in CHF patients with ESRD on dialysis in terms of SCr and serum potassium levels. The gene discussed is NPPB; the disease is hydrops fetalis.